NCT01740531

Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion

A Randomized Controlled Study to Evaluate Efficacy and Safety of S 303 Treated Red Blood Cells (RBC) in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 86 (actual)
• Sponsor: Cerus Corporation · Industry
• Sex: All
• Age: 10 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy and safety of S 303 treated red blood cells (RBCs) in subjects who require chronic transfusion support due to thalassemia major.

Detailed description

To evaluate the efficacy and safety of S 303 treated red blood cells (RBCs) in subjects who require chronic transfusion support due to thalassemia major.

Conditions

• Thalassemia Major

Interventions

Type	Name	Description
BIOLOGICAL	S-303 Treated Red Blood Cells (RBCs)
BIOLOGICAL	Conventional, untreated Red Blood Cells

Timeline

• Start date: 2012-12-01
• Primary completion: 2017-12-21
• Completion: 2017-12-31
• First posted: 2012-12-04
• Last updated: 2018-07-18

Locations

3 sites across 2 countries: Italy, Turkey (Türkiye)